Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma

Laryngoscope

Volumn 117, Issue 6, 2007, Pages 1013-1018

  Cheng, Junping ^a,b   Ekberg, Tomas ^a   Engström, Mats ^a   Nestor, Marika ^a   Jensen, Holger J ^c   Tolmachev, Vladimir ^d   Anniko, Matti ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Rigshospitalet   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alpha emitter; Astatine 211; Chimeric monoclonal antibody; Head and neck squamous cell carcinoma; Nude mice; Radioimmunotherapy; U36

Indexed keywords

CHIMMONOCLONAL ANTIBODY U36; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY U36 AT 211; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; EXPERIMENTAL NEOPLASM; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CHIMERIN PROTEINS; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RANDOM ALLOCATION; STAINING AND LABELING;

EID: 34249889331     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31804b1a6d     Document Type: Article

References (15)

1. Carlsson J, Forssell-Aronsson E, Glimelius B, Mattsson S. Therapy with radiopharmaceuticals. Acta Oncol 2002;41:623-628.
2. Visser GW, Gerretsen M, Herscheid JD, et al. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-1963.
3. Colnot DR, Quak JJ, Roos JC, et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999-2010.
4. Zalutsky MR, Pozzi OR. Radioimmunotherapy with alphaparticle emitting radionuclides. Q J Nucl Med Mol Imaging 2004;48:289-296.
5. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res 2003;9:3914S-3921S.
6. van Hal NL, van Dongen GA, Stigter-van Walsum M, et al. Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. Int J Cancer 1999;82:837-845.
7. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004;53:567-579.
8. Schrijvers AH, Quak JJ, Uyterlinde AM, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-4390.
9. Sjostrom A, Tolmachev V, Lebeda O, et al. Direct astatination of a tumor-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group. J Radioanal Nucl Chem 2003:191-197.
10. Nestor M, Persson M, van Dongen GA, et al. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1296-1304.
11. McLendon RE, Archer GE, Larsen RH, et al. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys 1999;45:491-499.
12. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A 1993;90:8996-9000.
13. Verel I, Heider KH, Siegmund M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 2002;99:396-402.
14. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-1198.
15. Borjesson PK, Postema EJ, Roos JC, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003;9:3961S-3972S.